## **Special Issue**

# Structural and Computational-Driven Molecule Design in Drug Discovery

## Message from the Guest Editors

Drug development is a complicated, high-risk, expensive, and lengthy process along with several stages such as target identification, lead discovery and lead optimization. In this process, the congruence between computational and experimental outcomes is a mainstay for the exploration of novel compounds. Besides, in the drug development process, many drug candidates could not pass the trials successfully due to the inadequate ADMET properties. Therefore, in silico ADMET analysis is attractive and a cost-saving strategy for a large number of compounds prior to applying expensive and time-consuming in vitro and in vivo ADMET estimation. This Special Issue aims to provide deep mechanistic insights into strategies in structural dynamics studies and computational methods. It is our great pleasure to invite you to submit original research articles and reviews in a Special Issue on "Structural and Computational-Driven Molecule Design in Drug Discovery". Research areas may include (but are not limited to) the following: Structural dynamics studies Computer-aided drug design Molecular dynamics simulations Molecular docking Virtual screening QSAR In silico ADMET.

### **Guest Editors**

Dr. Halil İbrahim Ciftci

Dr. Belgin Sever

Dr. Hasan Demirci

## Deadline for manuscript submissions

closed (26 February 2024)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/145133

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

